All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
During SOHO 2019, Houston, US, Dr. Alessandra Ferrajoli from The University of Texas, MD Anderson Cancer Center, Houston, US, spoke to the Lymphoma Hub about new prognostic factors, and how they are used for the treatment of patients with chronic lymphocytic leukemia (CLL).
She highlights mutational status, as the most important prognostic factor, which should be supplemented with a cytogenetic assessment. Ferrajoli then follows on, describing other prognostic factors taken into account like the age of the patient and TP53 status. She highlights the need for reassessment before each line of therapy. Since only the mutational status of the IgG chain stays constant during disease progression.
What are the novel prognostic factors for the treatment of patients with CLL?
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox